(Q39591595)

13 September 2017

Limited success of HCV antiviral therapy in United States veterans (English)

1 reference

13 September 2017

0 references

United States of America

0 references

author name string

Cathey H Cawthorne

1

1 reference

13 September 2017

Kelly R Rudat

2

1 reference

13 September 2017

Mary S Burton

3

1 reference

13 September 2017

Kyle E Brown

4

1 reference

13 September 2017

Bruce A Luxon

5

1 reference

13 September 2017

Christine G Janney

6

1 reference

13 September 2017

Claus J Fimmel

7

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

The American Journal of Gastroenterology

13 September 2017

1 reference

13 September 2017

97

1 reference

13 September 2017

1

1 reference

13 September 2017

149-155

1 reference

Epidemiology of hepatitis C virus infection in American veterans

13 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05439.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05439.X

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05439.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05439.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05439.X

Hepatitis C therapy in treatment-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05439.X

Management of interferon relapsers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05439.X

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05439.X

Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05439.X

Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05439.X

Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellular carcinoma after liver transplantation than albumin mRNA in peripheral blood. Liver Transplant Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05439.X

10.1111/J.1572-0241.2002.05439.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference